KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $3.4 million.

  • Emergent BioSolutions' Capital Expenditures fell 4137.93% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 6441.72%. This contributed to the annual value of $22.9 million for FY2024, which is 5562.02% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Capital Expenditures of $3.4 million as of Q3 2025, which was down 4137.93% from $2.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Capital Expenditures high stood at $179.4 million for Q3 2022, and its period low was $1.7 million during Q4 2024.
  • For the 5-year period, Emergent BioSolutions' Capital Expenditures averaged around $30.7 million, with its median value being $12.5 million (2023).
  • Per our database at Business Quant, Emergent BioSolutions' Capital Expenditures skyrocketed by 22500.0% in 2022 and then tumbled by 9297.66% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Capital Expenditures (Quarter) stood at $45.8 million in 2021, then skyrocketed by 291.7% to $179.4 million in 2022, then plummeted by 93.65% to $11.4 million in 2023, then plummeted by 85.09% to $1.7 million in 2024, then surged by 100.0% to $3.4 million in 2025.
  • Its Capital Expenditures was $3.4 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.6 million in Q1 2025.